Andrew J. Roth

Articles

Aggressive Treatment Leads to Long-Term Survival in Low-Risk Stage IV NSCLC

September 16th 2014

Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival rate of patients with stage IV NSCLC.

Radiotherapy Without Chemo Can Ease Dysphagia in Patients With Advanced Esophageal Cancer

September 15th 2014

Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer

UCLA Researcher Provides Insight Into the Impact of Pembrolizumab in Melanoma

September 13th 2014

To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.

Advaxis Scientific Officer Illuminates ADXS-PSA/Pembrolizumab Collaborative Study

August 30th 2014

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Pembrolizumab Combination Study Planned in Prostate Cancer

August 27th 2014

Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.

Favorable Safety Profile of T-DM1 Confirmed in Large Study

August 13th 2014

The favorable safety profile of T-DM1 makes it apt to be looked at in other settings of breast cancer.

Sorafenib Does Not Improve PFS in Phase III Breast Cancer Study

July 25th 2014

A phase III trial analyzing sorafenib for the treatment of patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival.

Risk of Recurrence Low in Small, HER2-Positive Breast Tumors

July 15th 2014

Patients with small, node-negative, HER2-positive breast cancer tumors had a low risk of invasive recurrence after 5 years

FDA Approves Belinostat for Peripheral T-Cell Lymphoma

July 3rd 2014

The FDA has approved belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Blinatumomab Receives Breakthrough Therapy Designation for ALL

July 1st 2014

The FDA has granted a breakthrough therapy designation to blinatumomab for the treatment of adult patients with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

FDA Approves Lymphoseek for Head and Neck Cancer

June 13th 2014

The FDA has approved the radioactive diagnostic imaging agent Lymphoseek (technetium 99m tilmanocept) Injection to guide sentinel lymph node biopsy in patients with cancer of the head and neck.

FDA Approves Gadobutrol for MRI Evaluation of Breast Cancer

June 13th 2014

The FDA has approved gadobutrol (Gadavist) injection for intravenous use with breast MRI to detect and identify the extent of disease

Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study

April 23rd 2014

A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma

Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer

April 15th 2014

Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.

New ASCO Guideline Expands Recommendation for SLN Biopsy Use in Early Stage Breast Cancer

April 11th 2014

An updated guideline from ASCO regarding the use of sentinel lymph node (SLN) biopsy in early stage breast cancer supports the use of the procedure over axillary lymph node dissection (ALND) in a larger group of patients than previously recommended.

PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC

April 7th 2014

PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma

Exceptional Responder Provides Treatment Clues in Bladder Cancer

March 13th 2014

An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib.

Anti-PD-1 Antibody MK-3475 Advances Into Multiple Tumor Types

February 7th 2014

Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of its investigational anti-PD-1 immunotherapy MK-3475 across multiple tumor types

FDA Reauthorizes Sale of Ponatinib

December 20th 2013

The FDA has approved revised US Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig® (ponatinib).

Updated Results Confirm Aldoxorubicin Superiority in STS

December 19th 2013

Aldoxorubicin demonstrated significant benefit to progression-free survival (PFS) compared with doxorubicin in patients with first-line, metastatic, locally advanced or unresectable soft tissue sarcomas